Overview

Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict response to treatment and survival.

Phase:

Phase 2

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Cetuximab